Staff
Rob Tankson is a serial entrepreneur, angel investor, and co-founder and COO of PrestoDoctor. With his leadership and vision, PrestoDoctor was acquired by Cannabis Sativa Inc. (OTCQB: CBDS) in August 2017 at a $11m valuation. Rob currently serves on the board of Cannabis Sativa.
Prior to co-founding PrestoDoctor in 2015, Rob worked in the finance and tech industries, including at Google, ClearSlide, and Pacific Wealth Group. While at Google, he managed expense planning, reporting, and analysis for emerging products. After Google, Rob worked on Wall Street as an equity research analyst where he developed a unique forward-looking database to quickly identify changes in industry trends, successfully outperforming the S&P 500 annually. Rob received his BA in Psychology from the University of San Francisco.
Full birth name: Robert Nehemiah Tankson, III
Title: Co-Founder and COO
Company: PrestoDoctor
Years at current company: 6
Education profile: I received my BA in Psychology from the University of San Francisco.
Most successful professional accomplishment before cannabis:
During my time on Wall Street as an equity research analyst, I developed a unique forward-looking database to quickly identify changes in industry trends, successfully outperforming the S&P 500 annually. Earlier in my career, I drove $3.4M+ in new revenue and opportunities for the tech company, ClearSlide. When I was at Google, I increased Chromebook revenue and built tech company partnerships across five key U.S. markets.
Company Mission:
PrestoDoctor’s mission is to provide cannabis access and education while upholding our high standards in customer service, performance, and professionalism. We are industry pioneers, thought leaders, and continually strive to become the most respected cannabis telemedicine brand in the United States, and eventually globally.
Company’s most successful achievement:
We’ve reached more than 200,000 patients across eight states and overcome the industry’s inability to leverage traditional advertising and marketing practices. Since we launched, we’ve pursued partnerships, rolled out an affiliate program, and launched virtual clinics to offer services at events nationwide. We were able to accelerate our expansion by securing partial acquisition by Cannabis Sativa, Inc. to generate funding.
We are part of a powerful movement. People have been fighting for medical cannabis for decades. Until cannabis is federally legal, we will do our part and provide access to as many people as we can and we are committed to helping the healthcare communities to really see cannabis as medicine, change federal law, and get cannabis covered by insurance.
Has the company raised any capital (yes or no):
if so, how much?:
Yes, we sold 51% of the company in 2017 in an 8-figure deal to publicly traded Cannabis Sativa, Inc. Before that, the company was self-funded/bootstrapped.
Any plans on raising capital in the future?
Yes, we are exploring capital raise to further expand our reach in the US cannabis market and eventually globally. We are also exploring other industries in which our telemedicine platform could be utilized.
Most important company 5-year goal:
To complete our U.S. expansion, have a presence in other global markets, and be the most trusted brand in medical cannabis. From the start, our mission has been to provide easier access to medical cannabis utilizing our telemedicine platform. We have a proven concept with nearly 20,000 5-star patient reviews and are excited to accelerate and further scale operations.
